Page last updated: 2024-11-04

vorinostat and Viremia

vorinostat has been researched along with Viremia in 6 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Viremia: The presence of viruses in the blood.

Research Excerpts

Excerpt	Relevance	Reference
"Tamoxifen did not enhance vorinostat-induced HIV transcription (between-arm ratio, 0."	3.11	Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. ( Aga, E; Archin, N; Bosch, RJ; Chomont, N; Connick, E; Coxen, K; Deeks, S; Dobrowolski, C; Ehui, L; Gandhi, M; Gandhi, RT; Giguel, F; Godfrey, C; Hosey, L; Howell, BJ; Karn, J; Kuritzkes, DR; Ma, Q; Morse, GD; Scully, EP; Sieg, SF; Squires, KE; Starr, K; Tsibris, A; Wu, G, 2022)

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (66.67)	24.3611
2020's	2 (33.33)	2.80

Authors

Authors	Studies
Gay, CL	1
James, KS	1
Tuyishime, M	1
Falcinelli, SD	1
Joseph, SB	1
Moeser, MJ	1
Allard, B	1
Kirchherr, JL	1
Clohosey, M	1
Raines, SLM	1
Montefiori, DC	1
Shen, X	1
Gorelick, RJ	1
Gama, L	1
McDermott, AB	1
Koup, RA	1
Mascola, JR	1
Floris-Moore, M	1
Kuruc, JD	2
Ferrari, G	1
Eron, JJ	2
Archin, NM	2
Margolis, DM	2
Scully, EP	1
Aga, E	1
Tsibris, A	1
Archin, N	1
Starr, K	1
Ma, Q	1
Morse, GD	1
Squires, KE	1
Howell, BJ	1
Wu, G	1
Hosey, L	1
Sieg, SF	1
Ehui, L	1
Giguel, F	1
Coxen, K	1
Dobrowolski, C	1
Gandhi, M	1
Deeks, S	1
Chomont, N	1
Connick, E	1
Godfrey, C	1
Karn, J	1
Kuritzkes, DR	1
Bosch, RJ	3
Gandhi, RT	1
Cillo, AR	1
Sobolewski, MD	1
Fyne, E	1
Piatak, M	2
Coffin, JM	2
Mellors, JW	1
Ling, B	1
Rogers, L	1
Johnson, AM	1
Russell-Lodrigue, K	1
Hazuda, DJ	2
Lifson, JD	1
Veazey, RS	1
Barton, K	1
Hiener, B	1
Winckelmann, A	1
Rasmussen, TA	1
Shao, W	1
Byth, K	1
Lanfear, R	1
Solomon, A	1
McMahon, J	1
Harrington, S	1
Buzon, M	1
Lichterfeld, M	1
Denton, PW	1
Olesen, R	1
Østergaard, L	1
Tolstrup, M	1
Lewin, SR	1
Søgaard, OS	1
Palmer, S	1
Liberty, AL	1
Kashuba, AD	1
Choudhary, SK	1
Crooks, AM	1
Parker, DC	1
Anderson, EM	1
Kearney, MF	1
Strain, MC	1
Richman, DD	1
Hudgens, MG	1

Clinical Trials (11)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
IGHID 11802 - Combination Therapy With the Novel Clearance Modality (VRC07-523LS) and the Latency Reversal Agent (Vorinostat) to Reduce the Frequency of Latent, Resting CD4+ T Cell Infection (The VOR-07 Study)[NCT03803605]	Phase 1	15 participants (Actual)	Interventional	2019-02-12	Completed
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors[NCT03382834]	Phase 2	31 participants (Actual)	Interventional	2018-04-26	Active, not recruiting
Investigation of the Impact of Inducible, Replication-competent Latent HIV-1 as an Impediment to HIV/AIDS Cure in the Context of Sustained Viral Suppression[NCT04938518]		222 participants (Anticipated)	Observational [Patient Registry]	2019-05-01	Recruiting
Evaluation of the Efficacy and Mechanisms of a Novel Intervention for Chronic Pain Tailored to People Living With HIV[NCT03692611]		280 participants (Actual)	Interventional	2019-08-14	Active, not recruiting
A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection[NCT02475915]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2015-01-31	Completed
IGHID 1309 -A Phase I Study to Evaluate the Kinetics of the Immunologic Response and Virologic Impact of AGS-004 in HIV-Infected Individuals Suppressed on Antiretroviral Therapy Initiated During Acute and Chronic HIV Infection[NCT02042248]	Phase 1	6 participants (Actual)	Interventional	2014-03-31	Completed
Simultaneous Disruption of Latency and Immune Enhancement by Poly-ICLC During HIV-1 Infection[NCT02071095]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2014-04-30	Completed
IGHID 1320 - A Phase I Study to Evaluate the Safety, Immunologic, and Virologic Responses of HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) as a Therapeutic Strategy in HIV-Infected Individuals Started on Antiretroviral Therapy During Acute and Chr[NCT02208167]	Phase 1	6 participants (Actual)	Interventional	2015-04-07	Completed
A Phase I/II Investigation of the Effect of Vorinostat (VOR) on HIV RNA Expression in the Resting CD4+ T Cells of HIV-Infected Patients Receiving Stable Antiretroviral Therapy[NCT01319383]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2011-02-28	Completed
Research In Viral Eradication of HIV Reservoirs[NCT02336074]	Phase 2	60 participants (Actual)	Interventional	2015-11-27	Completed
IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900]	Phase 1	6 participants (Actual)	Interventional	2016-03-31	Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE)

The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017 was used to measure safety where Grade 3 is defined as severe and Grade 4 is defined as potentially life-threatening. Treatment-Related AEs assessments are considered related to study product as possible, probable, or definite as defined in the protocol. (NCT03803605)
Timeframe: First day of study treatment through end of study, a total of approximately 36 weeks

Intervention	percentage of participants (Number)
VRC07-523LS + Vorinostat (VOR)	0

Change From Baseline in Cell-associated HIV-1 RNA in CD4+ T Cells

Baseline is defined as the average of the pre-entry and entry values. Change was calculated as the value of Cell-associated HIV-1 RNA on Day 38 (5 hours post vorinostat) minus the value at baseline. (NCT03382834)
Timeframe: Pre-entry, entry, and Day 38

Intervention	log10 copies/million CD4 cells (Mean)
Arm A: Tamoxifen + Vorinostat	0.06
Arm B: Vorinostat Alone	0.17

Change From Baseline in Total HIV-1 DNA Levels in CD4+ T Cells

Baseline is defined as the average of the pre-entry and entry values. Change was calculated as the value of Total HIV-1 DNA on Day 38 (5 hours post vorinostat) minus the value at baseline. (NCT03382834)
Timeframe: Pre-entry, entry, and Day 38

Intervention	log10 copies/million CD4 cells (Mean)
Arm A: Tamoxifen + Vorinostat	0
Arm B: Vorinostat Alone	-0.04

Proportion of Participants With New Grade 3 or Greater Adverse Events

Proportion of participants with new Grade 3 or greater adverse events that are considered definitely, probably, or possibly related to study treatment (as judged by the core protocol team). The DAIDS AE Grading Table (corrected Version 2.1, July 2017) was used. (NCT03382834)
Timeframe: Measured from study entry through Day 65

Intervention	proportion of participants (Number)
Arm A: Tamoxifen + Vorinostat	0
Arm B: Vorinostat Alone	0

Number of Participants With HIV-1 RNA Levels (Measured by Single Copy Assay) Greater or Equal to the Lower Limit of Quantification

Number of participants with HIV-1 RNA levels measured by single copy assay (SCA) greater or equal to the lower limit of quantification (LOQ). The lower limit of quantification for this study was 0.47 copies/mL. (NCT03382834)
Timeframe: Pre-entry, entry, Day 28, Day 35, Day 38 (5 hours post vorinostat), Day 45, Day 65

Intervention	Participants (Count of Participants)
	Pre-entry SCA >= LOQ	Entry SCA >=LOQ	Day 28 SCA >=LOQ	Day 35 SCA >=LOQ	Day 38 SCA >=LOQ	Day 45 SCA >=LOQ	Day 65 SCA >=LOQ
Arm A: Tamoxifen + Vorinostat	10	9	11	11	7	9	10
Arm B: Vorinostat Alone	6	3	4	5	5	4	5

CD8 CD38 (Mean of Fluorescence)

the CD38-activation marker on CD8 T-cells (CD8/CD38). (NCT02071095)
Timeframe: Day 8

Intervention	mean fluorescent intensity (MFI) (Mean)
Arm A: Poly-ICLC	8.69
Arm B: Normal Saline	2.35

NK Cell Number

Natural killer cells or NK cells are part of the innate immune defense against infection and cancer. (NCT02071095)
Timeframe: at 48 weeks

Intervention	cells/µL (Mean)
Arm A: Poly-ICLC	20.68
Arm B: Normal Saline	19.41

Number Participants With Adverse Events

Safety measured by number of participants with adverse events. (NCT02071095)
Timeframe: Up to 48 weeks

Intervention	Participants (Count of Participants)
Arm A: Poly-ICLC	11
Arm B: Normal Saline	3

Percent Change in CD4+ Tcell-associated HIV-1 RNA as Compared to Baseline

CD4+ Tcell-associated HIV-1 RNA to determine whether Poly-ICLC disrupts viral latency in HIV-1-infected individuals on anti-retroviral therapy.Viral transcription assessed by monitoring cell associated HIV-1 RNA. Percent change compared to baseline. (NCT02071095)
Timeframe: Baseline, Day 2, Day 4, Day 8, Day 28

Intervention	percent change (Mean)
	Day 2	Day 4	Day 8	Day 28
Arm A: Poly-ICLC	102.8	134.8	161.0	199.6
Arm B: Normal Saline	186.3	254.7	66.33	126.7

Plasma Interferon-gamma-inducible Protein-10 (IP-10) Level

One of the biomarkers of cellular immune activation and exhaustion quantified by flow cytometry. Normal range is 7.8-500 pg/ml. (NCT02071095)
Timeframe: Day 2 and Day 4

Intervention	pg/ml (Mean)
	Day 2	Day 4
Arm A: Poly-ICLC	381.43	450.51
Arm B: Normal Saline	100.65	139.39

Number of Participants Developing Cancer Within 5 Years Following >/= 8 Vorinostat Dose Exposures

Development of a new cancer within the 5 years of taking their last dose of VOR 400 mg PO.All participants receiving one or more doses of VOR 400 mg PO in any and all Arms of the study. Pre-specified to be reported as one group. (NCT01319383)
Timeframe: From last dose Vorinostat to 5 years afterwards

Intervention	Participants (Count of Participants)
1/Single and Multiple Dose, Step 3	0
2/Interval Doses (Multiple) Step 4	0

Number of Participants Exhibiting an in Vivo Resting CD4+ T Cell- Associated HIV RNA (RCVL) Increase After Receiving a Single Dose of VOR 400 mg PO

Participants in Arm 1 and 2 were analyzed in Step 2 for an in vivo increase in resting CD4+ T cell- associated HIV RNA (RCVL) after administration of a single dose of VOR 400 mg PO (NCT01319383)
Timeframe: Arm1: Baseline, Visit 5 and Arm 2: Baseline and Visit 3

Intervention	Participants (Count of Participants)
1/Single & Multiple Dose, Step 2, Visit 5	8
2/Interval Dosing, Visit 3	4

Number of Participants Exhibiting an in Vivo Resting CD4+ T-cell-associated HIV RNA (Rc-RNA) Increase Following Each of Two Multiple Dose Cycles (11 Doses/Cycle)

Participants in Arm 1, Step 3 were analyzed for an in vivo increase in the resting CD4+ T cell- associated HIV RNA (RCVL) after 11 doses of VOR 400 mg PO. This cycle was repeated after a 5 - 8 week rest period for a 2nd series and measurement. (NCT01319383)
Timeframe: Baseline, Visit 18, Visit 29

Intervention	Participants (Count of Participants)
Arm 1 - Single and Multiple Dose, Step 3	0

Number of Participants Exhibiting an in Vivo Resting CD4+ T-cell-associated HIV RNA (Rc-RNA) Increase Following Multiple (n = 10) Interval Doses

Participants in Arm 2, Step 4 were analyzed for an in vivo increase in the resting CD4+ T cell- associated HIV RNA (RCVL) after administration of 10 doses of VOR 400 mg PO, given 72 hours apart. (NCT01319383)
Timeframe: Baseline, Visit 9

Intervention	Participants (Count of Participants)
Interval Doses (Multiple) Step 4	3

Number of Participants With a Significant in Vivo Response in Resting Cell Infection (RCI) and HIV RNA After Paired Doses

Induction of significant in vivo RCI and RCLV response after 2 doses of VOR 400 mg PO administered 48 hours apart or 72 hours apart (NCT01319383)
Timeframe: Baseline, Visit 6

Intervention	Participants (Count of Participants)
Interval Dosing , Step 3 (48 hr Interval)	0
Interval Dosing, Step 3 (72 Hour Interval)	6

Number of Participants With Confirmed Hematologic Toxicity >/= Grade 2 and Related to VOR Per Division of AIDS (DAIDS) Grading Table

DAIDS Grading Table- Grade 1- mild, Grade 2- moderate; Grade 3- severe Grade 4- potentially life-threatening. Pre specified to combine all participants into one arm. (NCT01319383)
Timeframe: 24 hrs following single dose and 1 week after last of multiple dose sequence

Intervention	Participants (Count of Participants)
1/Single & Multiple Dose, Steps 2 and 3	0
2/Interval Dosing, Steps 2, 3 and 4	0

Number of Participants With Confirmed Non-hematologic Toxicity >/= Grade 3 and Related to VOR Per Division of AIDS (DAIDS) Grading Table

Intervention	Participants (Count of Participants)
1/Single & Multiple Dose, Steps 2 and 3	0
2/Interval Dosing, Steps 2, 3 and 4	0

Number of Participants With Measurable Changes in Plasma HIV-1 RNA

Assess for detectible HIV-1 RNA > 150 copies/mL, confirmed by repeat evaluation, following VOR dose. By standard assay and single copy assay. Pre specified to combine all participants into one arm. (NCT01319383)
Timeframe: 1 week after last VOR dose

Intervention	Participants (Count of Participants)
1/Single & Multiple Dose, Steps 2 and 3	0
2/Interval Dosing, Steps 2, 3 and 4	0

Histone H4 Acetylation

Histone H4 acetylation using a H4K5/8/12/16 immunoassay with thawed PBMC derived cell lysates added to an ELISA using anti-H4 monoclonal antibody (NCT02336074)
Timeframe: 12 weeks

Intervention	Fold increase pre to post vorinostat (Mean)
Intervention (Arm B - ART + Vaccines + Vorinostat)	3.19

Quantitative Viral Outgrowth

Number of Participants with undetectable quantitative viral outgrowth (NCT02336074)
Timeframe: At week 16

Intervention	Participants with undetectable outgrowth (Number)
Control (Arm A - ART Only)	12
Intervention (Arm B - ART + Vaccines + Vorinostat)	6

Total HIV DNA From CD4 T-cells

The average of two measures taken at post-randomisation week 16 and 18 (NCT02336074)
Timeframe: Averaged across post-randomisation week 16 and 18

Intervention	HIV-DNA copies/mill CD4+ T cells (log10) (Mean)
Control (Arm A - ART Only)	2.95
Intervention (Arm B - ART + Vaccines + Vorinostat)	3.06

Viral Inhibition

"CD8+ T cell antiviral suppressive activity was expressed as percentage elimination and determined as follows: [(fraction of p24+ cells in CD4+ T cells cultured alone) - (fraction of p24 + in CD4+ T cells cultured with CD8+ cells)]/(fraction of p24+ cells in CD4+ T cells cultured alone) × 100.~Viral inhibition Assay" (NCT02336074)
Timeframe: 12 weeks

Intervention	Percentage elimination (Mean)
Control (Arm A - ART Only)	-18.25
Intervention (Arm B - ART + Vaccines + Vorinostat)	1.50

CD8+ T-cell Responses

Percentage of CD8+ CD107a+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks

Intervention	% cells CD8+ CD107a+ IFNγ+ (Median)
	Post randomisation week 9	Post randomisation week 12
Control (Arm A - ART Only)	0.052	0.062
Intervention (Arm B - ART + Vaccines + Vorinostat)	0.194	0.263

Percentage of CD4+ CD154+ IFNγ+ T Cells

Percentage of CD4+ CD154+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks

Intervention	% cells CD4+ CD154+ IFNγ+ (Median)
	Post randomisation week 9	Post randomisation week 12
Control (Arm A - ART Only)	0.006	0.006
Intervention (Arm B - ART + Vaccines + Vorinostat)	0.097	0.109

Trials

2 trials available for vorinostat and Viremia

Article	Year
Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 10-12, Volume: 75, Issue:8 Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; DNA; Estrogen Receptor alpha; Female	2022
Broad activation of latent HIV-1 in vivo. Nature communications, 2016, 09-08, Volume: 7 Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; DNA, Viral; Drug Administration Schedule; HIV In	2016

Article

Year

Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 10-12, Volume: 75, Issue:8

Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; DNA; Estrogen Receptor alpha; Female

2022

Broad activation of latent HIV-1 in vivo.

Nature communications, 2016, 09-08, Volume: 7

Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; DNA, Viral; Drug Administration Schedule; HIV In

2016

Other Studies

4 other studies available for vorinostat and Viremia

Article	Year
Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. The Journal of infectious diseases, 2022, 03-02, Volume: 225, Issue:5 Topics: Broadly Neutralizing Antibodies; CD4-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Viremia;	2022
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2014, May-13, Volume: 111, Issue:19 Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation,	2014
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2014, May-13, Volume: 111, Issue:19 Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation,	2014
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2014, May-13, Volume: 111, Issue:19 Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation,	2014
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2014, May-13, Volume: 111, Issue:19 Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation,	2014
Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaques. PloS one, 2014, Volume: 9, Issue:7 Topics: Animals; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Darunavir; DNA, Viral; Drug Therapy, Co	2014
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, Jul-25, Volume: 487, Issue:7408 Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi	2012